Jennifer Buell - Jan 21, 2022 Form 4 Insider Report for MiNK Therapeutics, Inc. (INKT)

Role
President, Chief Executive Officer, Director
Signature
By: /s/ Christine Klaskin, attorney-in-fact
Stock symbol
INKT
Transactions as of
Jan 21, 2022
Transactions value $
$0
Form type
4
Date filed
1/25/2022, 04:20 PM
Previous filing
Oct 20, 2021
Next filing
Jan 11, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction INKT Stock Option (Right to Buy) Award $0 +680K $0.00 680K Jan 21, 2022 Common Stock 680K $3.12 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents an option to purchase shares of the common stock, which vests as to 35% of the underlying shares on January 21, 2025 and as to the remaining 65% of the underlying shares on January 21, 2026; provided that the Reporting Person maintains a business relationship with the Issuer through each such vesting date.

Remarks:

President, Chief Executive Officer